Doctors in China report the first sequential use of efgartigimod and telitacicept to rescue a 73-year-old MuSK-myasthenia ...

Blocking a receptor called P2X7 significantly reduced inflammation in human brain tissue, revealing a potential new treatment strategy for neurological and psychiatric disorders. The discovery could ...

It's a 'singular and unparalleled' event.

New data show deepening improvement in ocular MG and sustained one-year efficacy in anti-AChR antibody-negative MG – broadening VYVGART's ...

To understand the economic devastation Iran is now experiencing, look no further than the trucks choking its borders. Thousands of them have lined up at land crossings into neighboring Turkey and ...

Most local anesthetics used in medicine last only eight to 12 hours, or a day at most. Now, Boston Children's Hospital researchers have formulated a more effective slow-release injectable drug ...

As US President Donald Trump tries to force Iran into submission, a naval blockade is proving to be his tool of choice. But the operation is testing the limits of the American military, exhausting ...

Sugammadex is a modified γ-cyclodextrin widely used in clinical practice to reverse neuromuscular blockade induced by non-depolarizing neuromuscular blockade agents, notably rocuronium and vecuronium.

Andrew covers the biopharma industry, scientific research, and public health across the continent. You can reach Andrew confidentially on Signal at drewqjoseph.71. An experimental drug for a rare ...

Novartis said an experimental drug for neuromuscular disease myotonic dystrophy type 1 didn't meet the primary goal in a late-stage trial. The drug, del-desiran, was one of the three therapies the ...

Novartis NOVN-1.46%decrease; down pointing triangle shares dropped as much as 10% after the drugmaker said an experimental neuromuscular treatment failed a late-stage clinical trial, the latest blow ...